Diabetic Foot UlcerPhase 4NCT01835379
Study of Oasis Ultra in Diabetic Foot Ulcers
A Phase 4 study testing Oasis and Standard in people with Diabetic Foot Ulcer, run by Healthpoint at 16 sites in United States.
Trial summary
Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot Ulcer
- What is being tested?
- Oasis and Standard
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 82 participants
- Where
- 16 sitesUnited States
- Study dates
- May 2013to Sep 2014
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
- Subjects 18 years of age or older of either sex with a history of diabetes mellitus (Type 1 or 2) requiring medication (insulin and/or oral/injectable) to control blood glucose levels.
- A non-healing, Wagner grade 1 or 2, neuropathic diabetic foot ulcer.
- Willing and able to make all required study visits.
- Able to follow instructions.
- An ulcer present on any part of the plantar surface of the foot, which is 0.5 cm2 to 10 cm2 (inclusive), as measured at the Screening Visit prior to debridement, with a duration ≥ 6 weeks (documented in the patient's history or by patient report of onset) but not more than 12 months.
Show all 21Show fewer
- Separation of at least 5 cm (wound edge to wound edge) if ≥ 2 wounds are present.
- Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a transcutaneous oxygen pressure (TcPO2) ≥ 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable in lieu of ABI, but if both are obtained, each must meet its respective cutoff.
- Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable (test result must be included in the source document).
- Target ulcer is not infected based on clinical assessment.
- Able to perform any required dressing changes at home or have a caregiver who can perform the dressing changes.
- Willing to use an appropriate off-loading device to keep weight off of foot ulcers.
- Blood counts and blood chemistry values as follows:
- Alanine aminotransferase (ALT) ≤ 3x upper limit of normal
- Aspartate aminotransferase (AST) ≤ 3x upper limit of normal
- Serum albumin ≥ 2.0 g/dL •Pre-albumin levels of ≥ 10 mg/dL
- Alkaline phosphatase ≤ 500 U/L •Serum total bilirubin ≤ 3.0 mg/dL
- Serum BUN < 75 mg/dL •Serum creatinine ≤ 4.5 mg/dL
- HbA1c ≤ 12% •Hemoglobin (Hgb) > 8.0 g/dL
- WBC > 2.0 x 109/L •Absolute neutrophil count > 1.0 x 109/L
- Platelet count > 50 x 109/L
Who cannot join
- Contraindications or hypersensitivity to the use of the study device or its components (e.g., porcine sensitivity).
- Participation in another investigational study within thirty (30) days of Visit 1 or planned participation overlapping with this study.
- Subjects with evidence of gangrene on either lower limb.
- Ulcers that require negative pressure or hyperbaric oxygen therapy.
- The Medical Monitor may declare any subject ineligible for a valid medical reason.
- Current treatment with disallowed medications or therapies. Subjects may not be enrolled into the study while using systemic antibiotics.
Trial locations and contacts
16 sites in 1 country.
16 sites in 1 country
United States16 sites
Study site
Bayonne, New Jersey, 07002
Study site
Carlsbad, California, 92009
Study site
Dallas, Texas, 75224
Study site
Dallas, Texas, 75243
Study site
Evansville, Indiana, 47713
Study site
Fair Oaks, California, 95628
Study site
Fort Worth, Texas, 76104
Study site
Fresno, California, 93720
Study site
Houston, Texas, 77036
Study site
Little Rock, Arkansas, 72205
Study site
Madisonville, Kentucky, 42431
Study site
McAllen, Texas, 78501
Study site
Saginaw, Michigan, 48602
Study site
San Diego, California, 92103
Study site
Shreveport, Louisiana, 71101
Study site
Virginia Beach, Virginia, 23464
About this study
Official title: A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra. The hypothesis to be tested is that application of Oasis Ultra will cause more diabetic foot ulcers to heal than wounds treated with regular medical care. Subjects will have their diabetic foot wounds treated for up to 12 weeks with Oasis Ultra or regular medical care .
- Conditions
- Diabetic Foot Ulcer
- Being tested
- Oasis, Standard
- Keywords
- Diabetes, Diabetic Foot Ulcer, Diabetic Foot Wound, Non-healing foot wound, Oasis, Diabetic neuropathy
- Medical subject headings
- Diabetic Foot, Diabetes Mellitus, Diabetic Neuropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OasisDevice
Oasis Ultra will be applied once per week for up to 12 weeks.
StandardOther
Also called Standard Care
| Study group | Role | What they receive |
|---|---|---|
| Oasis | Experimental | Oasis Receives: Device: Oasis |
| Standard | Other | Standard Care Receives: Other: Standard |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Wounds Closed
Measured: At the end of 12 Weeks
Secondary outcomes (1)
Time to Wound Closure
Kaplan-Meier (K-M) analysis was employed to estimate the median time in weeks to complete ulcer closure.
Measured: During the 12 Week treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2013 (estimated)
- Study startMay 2013
- Primary completionSep 2014
- Study completionSep 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Diabetic Foot UlcerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 82 participants (actual)
Sponsor and investigators
- Lead sponsor
- Healthpoint
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Herbert B Slade, MD, Study chair, Healthpoint
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01835379
- Sponsor's protocol ID
- 815-999-09-010
- Status last verified
- Jan 2015
- First submitted
- 16 Apr 2013
- Last updated
- 22 Jan 2015
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers
- ClinicalTrials.gov ID
- NCT01835379
- Acronym / sponsor ID
- 815-999-09-010
- Conditions
- Diabetic Foot Ulcer
- Keywords
- Diabetes, Diabetic Foot Ulcer, Diabetic Foot Wound, Non-healing foot wound, Oasis, Diabetic neuropathy
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 82 participants (actual)
- Lead sponsor
- HealthpointIndustry (pharma, biotech, devices)
- Study start
- May 2013
- Primary completion
- Sep 2014 (actual)
- Study completion
- Sep 2014 (actual)
- First posted
- 18 Apr 2013 (estimated)
- Results
- Posted 22 Jan 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra. The hypothesis to be tested is that application of Oasis Ultra will cause more diabetic foot ulcers to heal than wounds treated with regular medical care. Subjects will have their diabetic foot wounds treated for up to 12 weeks with Oasis Ultra or regular medical care .
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Oasis | Experimental | Device: OasisOasis |
| Standard | Other | Other: StandardStandard Care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (21 listed)
- Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
- Subjects 18 years of age or older of either sex with a history of diabetes mellitus (Type 1 or 2) requiring medication (insulin and/or oral/injectable) to control blood glucose levels.
- A non-healing, Wagner grade 1 or 2, neuropathic diabetic foot ulcer.
- Willing and able to make all required study visits.
- Able to follow instructions.
Key exclusion criteria (6 listed)
- Contraindications or hypersensitivity to the use of the study device or its components (e.g., porcine sensitivity).
- Participation in another investigational study within thirty (30) days of Visit 1 or planned participation overlapping with this study.
- Subjects with evidence of gangrene on either lower limb.
- Ulcers that require negative pressure or hyperbaric oxygen therapy.
- The Medical Monitor may declare any subject ineligible for a valid medical reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OasisOasis Ultra will be applied once per week for up to 12 weeks. | Device | Oasis |
| StandardAlso: Standard Care | Other | Standard |
Primary outcome
Percentage of Wounds Closed
Time frame: At the end of 12 Weeks
1 secondary outcome
Time to Wound Closure
Time frame: During the 12 Week treatment period
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Diabetic Foot Ulcer
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Herbert B Slade, MD study chair
Healthpoint
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Oasis and Standard in people with Diabetic Foot Ulcer, run by Healthpoint at 16 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 21 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jan 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Wounds Closed (time frame: At the end of 12 Weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2015.